Kera Capital Partners Inc. Makes New Investment in AbbVie Inc. $ABBV

Kera Capital Partners Inc. purchased a new position in shares of AbbVie Inc. (NYSE:ABBV) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 8,391 shares of the company’s stock, valued at approximately $1,943,000.

A number of other hedge funds also recently made changes to their positions in ABBV. Vanguard Group Inc. grew its position in shares of AbbVie by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after acquiring an additional 3,380,842 shares during the period. Geode Capital Management LLC lifted its position in shares of AbbVie by 2.4% during the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after acquiring an additional 924,761 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of AbbVie by 6.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock worth $4,970,848,000 after acquiring an additional 1,517,222 shares during the period. Norges Bank purchased a new position in shares of AbbVie in the second quarter valued at $4,288,200,000. Finally, Raymond James Financial Inc. raised its stake in shares of AbbVie by 41.8% during the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after purchasing an additional 2,753,312 shares during the period. 70.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Scotiabank began coverage on shares of AbbVie in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective for the company. Cantor Fitzgerald set a $250.00 target price on AbbVie and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Erste Group Bank lowered AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Citigroup lowered their price objective on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research report on Monday, November 3rd. Finally, UBS Group reissued a “neutral” rating on shares of AbbVie in a research note on Tuesday. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average target price of $246.89.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck a three‑year voluntary agreement with the U.S. administration that exempts the company from tariffs and future pricing mandates while committing to major U.S. investment — a headline that reduces policy/regulatory uncertainty and signals long‑term U.S. capital deployment. Read More.
• Positive Sentiment: AbbVie signed an exclusive global licensing deal (up to ~$5.6B) with RemeGen for RC148, a PD‑1/VEGF bispecific — this meaningfully expands AbbVie’s oncology pipeline and long‑term growth optionality. Read More.
• Positive Sentiment: AbbVie is buying a drug‑delivery system and Arizona manufacturing facility from West Pharmaceutical and is investing in U.S. manufacturing (including a reported $175M plant spend) — supports supply chain control and the company’s U.S. investment pledge. Read More.
• Neutral Sentiment: AbbVie joined peers in urging FDA updates to post‑approval change rules — could improve manufacturing flexibility but is a regulatory/industry‑wide request with uncertain timing. Read More.
• Neutral Sentiment: A Phase 2 bipolar depression study (ABBV‑932) reached completion — a development milestone that requires readouts for directional impact. Read More.
• Negative Sentiment: Under the U.S. deal AbbVie agreed to provide lower prices in Medicaid (and expand affordable offerings) — a meaningful concession that could weigh on near‑term revenue and margins for affected products. Read More.

AbbVie Stock Up 0.2%

Shares of ABBV opened at $220.51 on Wednesday. The stock has a market capitalization of $389.72 billion, a P/E ratio of 167.05, a PEG ratio of 0.92 and a beta of 0.36. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The firm has a fifty day simple moving average of $226.84 and a two-hundred day simple moving average of $216.04.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period last year, the firm earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.1%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is presently 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.